Unclear results from the SUNRISE study leave questions about the potential of bezisterim for Parkinson’s

When a new drug is tested for Parkinson’s, we all hope for a clear answer: does it help or not? A recent announcement from the company BioVie about their experimental drug, bezisterim, has left many in the community feeling confused rather than hopeful. The company reported results from a study called SUNRISE, which looked at 57 people in the early stages of the condition who were not yet taking standard dopamine replacement medications like levodopa. While the company described the study as a success, they used a complicated method to present their data that has raised questions among scientists and doctors. Bezisterim is designed differently than the pills most of us take daily. While standard treatments focus on topping up dopamine to mask tremors or stiffness, bezisterim aims to tackle the root causes of cell damage, specifically brain inflammation and how the body handles insulin. The goal of the SUNRISE study was straightforward: to see if taking this drug for twelve weeks would improve motor symptoms, measured by the standard scale doctors use to track our movement, known as the Unified Parkinson's Rating Scale. When the results were shared, however, the company did not lead with that standard motor score. Instead, they introduced a new, custom measurement called the EPNIC 15. This is essentially a giant basket containing fifteen different categories, ranging from how we move to how we handle daily tasks and non motor symptoms. By combining these fifteen different things into one single score, the company reported that people taking bezisterim performed better than those on the placebo. In the world of medical research, creating a custom score after a study has already finished is controversial. It is like taking a test, failing the main questions, and then deciding to grade yourself on a mix of attendance, handwriting, and class participation instead. It makes it very difficult for us to know if the drug actually improved the specific movement issues it was intended to treat. When researchers looked closer at the original motor scores, they found that the drug did not work for everyone in the study. In fact, for people who started with low levels of inflammation in their blood, those taking a placebo actually did slightly better than those on the drug. The results suggest that bezisterim might be a targeted tool rather than a cure for everyone. It appears the drug may only provide benefits for people who have higher levels of inflammation at the start of their treatment. This is a common theme in modern research, where we are moving away from the idea of one drug for every person and toward "precision medicine" that matches the right treatment to the right biology. For those of us living with Parkinson's, this study serves as a reminder to look past the headlines. BioVie plans to use this information to design a larger trial that specifically screens for people with higher inflammation. If they can prove that the drug helps this specific group, it could still become a valuable addition to our toolkit. For now, it is not a proven solution, but rather a hint that we might eventually be able to treat the underlying inflammation that drives the condition in some people.